Irish plant for Wuxi Biologics

Source: Xinhua | 2018-05-03

HONG Kong-listed biopharma technology service provider Wuxi Biologics will invest 325 million euros (US$390 million) for a new biologics drug manufacturing facility in Ireland, the first overseas investment of its kind for a Chinese pharma company.

The 260,000-square-meter manufacturing site will be located at an industrial park in Dundalk in northern Ireland and is expected to create 400 new jobs and 700 construction jobs in phases over five years.

The site will begin construction in the first quarter in 2019 and be complete by the second quarter of 2021.

“Wuxi Biologics is a strong addition to Ireland’s growing cluster of next-generation bio-pharmaceutical companies and it also shows great commitment to Ireland with this project,” said Martin Shanahan, CEO of the Industrial Development Authority of Ireland, on Monday.